DLGAP5 anticorps (N-Term)
Aperçu rapide pour DLGAP5 anticorps (N-Term) (ABIN630974)
Antigène
Voir toutes DLGAP5 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- DLG7 antibody was raised against the N terminal Of Dlg7
-
Purification
- Affinity purified
-
Immunogène
- DLG7 antibody was raised using the N terminal Of Dlg7 corresponding to a region with amino acids EYERNRHFGLKDVNIPTLEGRILVELDETSQELVPEKTNVKPRAMKTILG
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
DLG7 Blocking Peptide, (ABIN938206), is also available for use as a blocking control in assays to test for specificity of this DLG7 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of DLG7 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- DLGAP5 (Discs, Large (Drosophila) Homolog-Associated Protein 5 (DLGAP5))
-
Autre désignation
- DLG7
-
Sujet
- DLG7 is a potential cell cycle regulator that may play a role in carcinogenesis of cancer cells. It is a mitotic phosphoprotein regulated by the ubiquitin-proteasome pathway. DLG7 is the key regulator of adherens junction integrity and differentiation that may be involved in CDH1-mediated adhesion and signaling in epithelial cells.
-
Poids moléculaire
- 95 kDa (MW of target protein)
-
Pathways
- M Phase
Antigène
-